Browse the evidence

Time restricted eating (TRE) will not be inferior to current practice (CP) in improving glycaemic control in individuals at risk of type 2 diabetes.

TRE may be a viable alternative dietary strategy for improving glucose control in at-risk individuals.

The HLC diet was more effective for improving the triglyceride to HDL-cholesterol ratio (TG/HDL-C) compared to the HLF diet.

The HLC diet may be preferred for improving lipid profiles in overweight adults.

Participants collectively lost 6,559 lbs over 12 months with a retention rate of 79%.

Weight loss interventions can be effective in a diverse group of healthy adults.

Weight loss was similar for Healthy Low-Fat and Healthy Low-Carbohydrate diets: -12.1 ± 1.1 lbs vs. -13.8 ± 1.0 lbs.

Both diet types can lead to similar weight loss outcomes.

Semaglutide is endorsed for obesity treatment following its FDA approval for type 2 diabetes.

Health practitioners can consider semaglutide as a treatment option for obesity.

Within both the Healthy Low-Fat (HLF) and Healthy Low-Carbohydrate (HLC) diet arms, the 12-month decrease in BMI was significantly greater for those in the High Quality/High Adherence subgroups compared to the Low Quality/Low Adherence subgroups.

Practitioners should emphasize the importance of both dietary quality and adherence for effective weight loss.

Improvement in dietary quality and adherence may influence weight loss success among those following low-fat and low-carbohydrate diets.

Encourage clients to improve both the quality of their diet and their adherence to dietary plans for better weight loss outcomes.

The Healthy Weight for Living (HWL) intervention resulted in a mean 6-month weight change of −8.8% for HWL and −8.0% for HWL + meal replacements (MR), both significantly better than controls (p < 0.001).

Implementing the HWL intervention can lead to significant weight loss in workplace settings.

Clinically meaningful weight loss (≥5%) was maintained at 18 months in both intervention groups.

The HWL intervention can lead to sustained weight loss over an extended period.

The HWL intervention can be delivered via videoconference and is effective with or without meal replacements.

Practitioners can implement the HWL intervention remotely, making it accessible for various workplace settings.

63.4% of survivors of adolescent and young adult cancer had ≥5% weight reduction after anti-obesity medication initiation.

Practitioners may consider AOMs as a viable option for weight management in this population.

The proportion of survivors with severe obesity decreased from 60% to 35% after anti-obesity medication initiation.

AOMs may effectively reduce severe obesity in this demographic.

Anti-obesity medications are effective for weight reduction in survivors of adolescent and young adult cancer.

AOMs can be considered a treatment option for weight management in AYA cancer survivors.

Semaglutide add-on to metformin significantly decreases the Visceral Adiposity Index (VAI) in type 2 diabetic patients, with the greatest reduction in the obesity group (-0.70).

Incorporating semaglutide with metformin may enhance fat loss in patients with type 2 diabetes, especially those with obesity.

Weight loss is associated with improvement in cardiovascular risk, menstrual cycles, ovulation, and pregnancy rate in women with obesity and PCOS.

Weight loss should be prioritized in treatment plans for women with obesity and PCOS to improve health outcomes.

Lifestyle modifications are often the first-line intervention for improving hormonal imbalances and menstrual cycles in women with PCOS.

Clinicians should consider lifestyle modifications as a primary strategy in managing PCOS.

Tirzepatide 10 mg was associated with a reduction in predicted 10-year risk of type 2 diabetes from 5.3% to 1.2%.

Practitioners may consider tirzepatide as an effective intervention for reducing diabetes risk in overweight or obese patients.

Tirzepatide 15 mg was associated with a reduction in predicted 10-year risk of type 2 diabetes from 4.9% to 1.0%.

Practitioners may consider tirzepatide as an effective intervention for reducing diabetes risk in overweight or obese patients.

Two-thirds of respondents reported reduced appetite, food cravings, or body weight.

Practitioners can expect that a significant portion of patients may experience appetite reduction and weight loss with Ozempic.

Tirzepatide yields greater weight loss and broad metabolic benefits.

Clinicians may prefer tirzepatide for patients focused on weight loss and metabolic improvements.

Exogenous β-hydroxybutyrate (BHB) supplementation significantly reduced fat mass by 2 kg and improved body fat percentage in overweight and obese adults.

Practitioners may consider BHB supplementation as a strategy to enhance fat loss in overweight and obese clients.

Lean mass was largely preserved with no declines in resting metabolic rate (RMR) in the BHB group.

BHB supplementation may help maintain lean mass during caloric restriction.

Patients treated with GLP-1RAs achieved a mean absolute weight loss of 7.33 kg compared to baseline.

GLP-1RAs can be effective for weight loss in IBD patients.

GLP-1 receptor agonist type drugs can help patients achieve considerable weight loss.

Practitioners can consider GLP-1 RAs as a treatment option for weight loss in obese patients.